Pfizer news - the latest biotech news from Labiotech.eu

Pfizer kicks $25M into CellCentric

Jim Cornall — Wed, 12 Jul 2023 12:00:00 +0000

U.K.-based biotechnology company CellCentric has received a strategic investment from Pfizer including $25 million to help finance further development of inobrodib, its first-in-class p300/CBP inhibitor to treat specific types of cancer. Pfizer will support CellCentric with its own clinical development program in multiple myeloma (MM) for 2024, alongside ongoing trials in specific hematological malignancies, through […]

The post Pfizer kicks $25M into CellCentric appeared first on Labiotech.eu.

© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

$5.5M funding for Oncopole to tackle cancer

Jim Cornall — Tue, 06 Jun 2023 09:49:05 +0000

Oncopole, Fonds de recherche du Québec – Santé (FRQS) cancer division in Canada, has received major investments that boost its public-private partnership model dedicated to the fight against cancer. Oncopole will continue to pursue its mission thanks to a $3 million reinvestment from founding partner Merck Canada. Oncopole, FRQS cancer division, is the result of […]

The post $5.5M funding for Oncopole to tackle cancer appeared first on Labiotech.eu.

Google Cloud adds AI solutions for drug discovery

Jim Cornall — Fri, 19 May 2023 08:49:37 +0000

Google Cloud has announced two new AI-powered life sciences solutions to accelerate drug discovery and precision medicine for biotech companies, pharmaceutical firms, and public sector organizations. The Target and Lead Identification Suite helps researchers better identify the function of amino acids and predict the structure of proteins; and the Multiomics Suite accelerates the discovery and […]

The post Google Cloud adds AI solutions for drug discovery appeared first on Labiotech.eu.

Promising results from phase 3 prostate cancer study

Jim Cornall — Fri, 05 May 2023 10:15:00 +0000

Astellas Pharma Inc. and Pfizer Inc. have announced trial results from a phase 3 study on prostate cancer. The results showed XTANDI (enzalutamide) plus leuprolide significantly reduced the risk of metastasis or death by 58% versus placebo plus leuprolide, as assessed by the primary endpoint of metastasis-free survival (MFS) in men with non-metastatic hormone-sensitive prostate […]

The post Promising results from phase 3 prostate cancer study appeared first on Labiotech.eu.

Gene therapy: a powerful tool for hemophilia B?

Roohi Mariam Peter — Tue, 18 Apr 2023 08:53:28 +0000

The approval of HEMGENIX, the first-ever gene therapy for hemophilia B, by the U.S. Food and Drug Administration (FDA) followed by the European Commission, has been momentous in rare disease therapeutic research, paving the way for various gene therapies that are currently being studied. As we observed World Hemophilia Day on April 17, let us […]

The post Gene therapy: a powerful tool for hemophilia B? appeared first on Labiotech.eu.

Pfizer’s $43B Seagen acquisition doubles early-stage oncology clinical pipeline

Jim Cornall — Tue, 14 Mar 2023 12:11:39 +0000

Pfizer Inc. is set to acquire Seagen Inc. for $229 in cash per Seagen share for a total enterprise value of $43 billion. Seagen is a global biotechnology company that discovers, develops and commercializes cancer medicines. The boards of directors of both companies have unanimously approved the transaction. “Pfizer is deploying its financial resources to […]

The post Pfizer’s $43B Seagen acquisition doubles early-stage oncology clinical pipeline appeared first on Labiotech.eu.

5 steps to strategic partnerships for healthtech startups

External Contributor — Thu, 02 Mar 2023 11:41:48 +0000

By Varvara Melikhova, founder and CEO of Unison Innovations Strategic partnerships are a better way to build a product’s capabilities than outright acquisitions. While the M&A path is set out for the most mature successful startups, early-stage partnerships can enhance a product’s market value and provide access to Big Pharma expertise and infrastructure, which significantly […]

The post 5 steps to strategic partnerships for healthtech startups appeared first on Labiotech.eu.

Innovation in life sciences requires collaboration and community

External Contributor — Wed, 18 Jan 2023 17:15:07 +0000

By Claudia Tripp and Katie Nelson, Kadans Science Partner Collaboration has underpinned some of the most impactful innovations of recent years. For example, the rapid development of the COVID vaccine was only made possible due to collaboration. Pfizer’s rapidly-established partnership with BioNTech delivered the first vaccine at lightning speed. Having established an ecosystem approach to […]

The post Innovation in life sciences requires collaboration and community appeared first on Labiotech.eu.

Pfizer diabetes and obesity study triggers Sosei Heptares windfall

Jim Cornall — Wed, 21 Dec 2022 09:30:38 +0000

Sosei Group Corporation has been notified by Pfizer that the first subject in a phase 2 clinical trial has been dosed with Pfizer’s candidate PF-07081532. This triggers a $10 million payment to Sosei Heptares. PF-07081532 is a once-daily, next-generation oral small molecule GLP-1 receptor agonist in development for the treatment of type 2 diabetes and obesity. […]

The post Pfizer diabetes and obesity study triggers Sosei Heptares windfall appeared first on Labiotech.eu.

Discovery Park celebrates 10 years and plans to double jobs over the next decade

Liza Laws — Wed, 16 Nov 2022 20:35:00 +0000

Plans to grow and double the number of people employed at Discovery Park, the UK’s biggest science and innovation center have been announced. The team behind its success shared the news as they celebrate a decade of delivering jobs and investment in the South East. Discovery Park marked the milestone by announcing its plans for […]

The post Discovery Park celebrates 10 years and plans to double jobs over the next decade appeared first on Labiotech.eu.

ASPIRE set up to collaborate on amyloidosis

Jim Cornall — Tue, 04 Oct 2022 14:45:17 +0000

A new group of biotech and pharma companies has been assembled by the Amyloidosis Research Consortium (ARC). ASPIRE (amyloidosis stakeholder partnerships for impact reach and equity), is a collaboration between biotech and pharmaceutical companies committed to advancing solutions, improving diagnosis and systems of care, and addressing obstacles to health equity on behalf of amyloidosis patients. […]

The post ASPIRE set up to collaborate on amyloidosis appeared first on Labiotech.eu.

Spinoff Biohaven launches with $258M and “incredible pipeline”

Jim Cornall — Tue, 04 Oct 2022 13:18:14 +0000

Biohaven Ltd. launched today as a new publicly traded company focused on delivering innovative life-changing treatments for neurological and neuropsychiatric diseases, including rare disorders. As of today, Biohaven has officially begun operating as a separate independent entity as part of the acquisition agreement with Pfizer in May 2022. The company, led by Vlad Coric as […]

The post Spinoff Biohaven launches with $258M and “incredible pipeline” appeared first on Labiotech.eu.

CytoReason and Pfizer agree deal worth up to $110M for AI drug discovery and development

Liza Laws — Tue, 20 Sep 2022 16:46:13 +0000

In a deal with a potential value of $110 million over the next five years, CytoReason has announced an extension of its multi-year partnership with Pfizer. Pfizer will make a $20 million equity investment under the terms of the agreement which will give the company the right to use CytoReason’s artificial intelligence (AI) technology and […]

The post CytoReason and Pfizer agree deal worth up to $110M for AI drug discovery and development appeared first on Labiotech.eu.

Moderna to sue Pfizer and German partner, BioNTech, for allegedly “copying technology”

Liza Laws — Fri, 26 Aug 2022 14:32:12 +0000

Moderna is today (August 26) filing patent infringement lawsuits against Pfizer and its partner BioNTech in both the U.S and Germany. The mRNA-focused biotech claims the companies’ Covid-19 vaccine Comirnaty infringes patents it led between 2010 and 2016 covering Moderna’s foundational mRNA technology which the company says was critical to the development of its own […]

The post Moderna to sue Pfizer and German partner, BioNTech, for allegedly “copying technology” appeared first on Labiotech.eu.

Cancer therapeutics company’s double win with $25M funding, and appointment of new board member

Liza Laws — Fri, 08 Jul 2022 16:27:16 +0000

An mRNA-technology company developing cancer therapeutics designed to improve patients’ survival rate and quality of life — this week announced the completion of a $25 million Series A financing. Kernal Biologics, Inc. (Kernal Bio) confirmed that the funding was led by Hummingbird Ventures. Amgen Ventures, HBM Genomics and Civilization Ventures along with other venture capitalists, family offices and […]

The post Cancer therapeutics company’s double win with $25M funding, and appointment of new board member appeared first on Labiotech.eu.

The COVID-19 pandemic has driven RNA therapeutics into the mainstream

Helen Albert — Mon, 04 Jul 2022 08:42:56 +0000

As messenger RNA vaccines save lives around the world, and RNA interference drugs are greenlit for rare diseases, the field of RNA therapeutics is now moving faster than ever before. The COVID-19 pandemic proved a turning point for the biotech companies BioNTech and Moderna, which specialize in developing technology based on messenger RNA (mRNA). The […]

The post The COVID-19 pandemic has driven RNA therapeutics into the mainstream appeared first on Labiotech.eu.

Sirana Pharma and Pfizer to work on treatment for brittle bone disease

Jim Cornall — Thu, 30 Jun 2022 08:49:15 +0000

German biotech company Sirana Pharma GmbH has entered into a collaborative research agreement with Pfizer Inc. to investigate the potential identification and validation of a novel treatment concept for a rare bone disease, osteogenesis imperfecta (OI). Also called brittle bone disease, the condition is currently lacking approved drugs. Sirana Pharma focuses on the development of […]

The post Sirana Pharma and Pfizer to work on treatment for brittle bone disease appeared first on Labiotech.eu.

Global call for scientists and inventors to form new startup

Liza Laws — Wed, 29 Jun 2022 20:34:07 +0000

A fourth start-up but the first of its kind sees some high-profile companies join forces in a hunt for new global research talent. AION Labs, an Israel-based alliance of AstraZeneca, Merck, Pfizer, Teva, Israel Biotech Fund and Amazon Web Services (AWS) are focusing their start-up on the ‘prediction of clinical trial outcome in biomarker-stratified cancer patient […]

The post Global call for scientists and inventors to form new startup appeared first on Labiotech.eu.

Millions invested for progression of Lyme disease vaccine

Liza Laws — Wed, 22 Jun 2022 19:02:42 +0000

Pfizer has agreed to invest €90.5 million ($95 million) towards a vaccination for Lyme disease. A deal has been struck with Valneva SE that will see the start of the phase 3 study of the disease’s vaccine candidate, VLA15. This is scheduled for the third quarter of this year. The investment will represent 8.1% of […]

The post Millions invested for progression of Lyme disease vaccine appeared first on Labiotech.eu.

Next-Gen Covid-19 Vaccines and Drugs Crowd into Late-Stage Trials

Jonathan Smith — Tue, 15 Feb 2022 11:16:00 +0000

Despite the widespread rollout of vaccines over 2021, the Covid-19 pandemic remains a threat to healthcare systems worldwide. Numerous treatments and vaccines are hitting the late-stage pipeline, which could greatly expand the anti-Covid-19 arsenal. Two years ago, the Covid-19 pandemic swept the world and left economic disruption, healthcare crises, and widespread lockdowns in its wake. […]

The post Next-Gen Covid-19 Vaccines and Drugs Crowd into Late-Stage Trials appeared first on Labiotech.eu.